Leader in Cancer Research named CEO of ZIOPHARM
NEW YORK, NY MAY 1 - Privately-held ZIOPHARM, Inc. announced it named Jonathan J. Lewis, MD, PhD, a founder of the company, to the position of chief executive officer.
Dr. Lewis has both academic expertise and industry recognition in product development, clinical trials strategy and management, and the direction of patient, support groups and opinion leader advocacy. With over 15 years of experience combined at Yale-New Haven Medical Center, Memorial Sloan-Kettering Cancer Center and Antigenics, Inc., Dr. Lewis has highly regarded leadership skills in translational research and product development, the cornerstones of ZIOPHARM's execution strategy.
While at Antigenics Dr. Lewis helped to raise over $100 million from investors, and his reputation with Wall Street, MD Anderson Cancer Center, and Memorial Sloan-Kettering Cancer Center led to a $5-million first-round private financing of ZIOPHARM. Dr. Lewis is a surgeon and molecular biologist by training.
About ZIOPHARM, Inc.
ZIOPHARM, Inc. is a privately held company founded in January 2004 to develop and commercialize a diverse, risk-sensitive portfolio of in-licensed cancer therapies. All products are focused on addressing unmet medical needs, with the potential for expedited approval and broad usage. For more information, please visit www.ziopharm.com